

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Diagens Biotechnology Co., Ltd.

杭州德適生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2526)

BOOK CLOSURE PERIOD FOR THE EXTRAORDINARY GENERAL MEETING

Hangzhou Diagens Biotechnology Co., Ltd. (the “**Company**”) proposes to hold an extraordinary general meeting (the “**EGM**”) on Thursday, July 23, 2026. The register of members of shares of the Company (the “**Shares**”) will be closed from Monday, July 20, 2026 to Thursday, July 23, 2026, both days inclusive, during which period no transfer of Shares will be effected. The record date for determining the eligibility of H shareholders to attend and vote at the EGM is Monday, July 20, 2026.

In order to determine the identity of members who are entitled to attend and vote at the EGM, all transfer documents accompanied by the relevant share certificates and transfer forms must be duly completed and lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, for registration not later than 4:30 p.m. on Friday, July 17, 2026.

A circular, which sets out the details of the resolution(s) to be proposed at the EGM, and a notice of the EGM will be published by the Company on or before July 8, 2026.

By Order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Dr. Song Ning
Chairman, Executive Director and General Manager

Hangzhou, PRC, July 3, 2026

As at the date of this announcement, the Board comprises (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.